This pilot program is designed to facilitate novel clinical and translational research that applies or accelerates discovery into testing in clinical or population settings. Projects will advance solutions by applying discoveries generated during research in the laboratory, and in preclinical studies in the areas of medicinal chemistry, computational chemistry, High Throughput Screening (HTS) and assay development, in vitro absorption–distribution–metabolism–excretion–toxicity (ADMET) and pharmacology and in vivo pharmacokinetics in clinical or population settings.
The Duke Clinical and Translational Science Institute (Duke CTSI) is the academic home of the National Institutes of Health’s Clinical and Translational Science Awards (CTSA) pilot funding programs at Duke University, is partnering with RTI International (RTI) to support new inter-institutional collaborative research teams.
Duke CTSI and RTI are interested in the following types of translational research projects that foster collaboration between the two institutions:
-
Research that generates translational discoveries relevant to human health or disease, regardless of whether the context of the discovery is the laboratory, in animal models or the field.
-
Research that applies or accelerates discovery into testing in clinical or population settings.
Deadlines:
-
Optional Letter of Intent (LOI): July 12, 2022
-
Application Submission Deadline: August 15, 2022